Table 3.
Cardiovascular outcomes for participants from Sale and Morwell.
| Outcome Variable | Morwell (Exposed) N = 336 |
Sale (Unexposed) N = 162 |
p-Value | ||
|---|---|---|---|---|---|
| Weighted Median | IQR | Weighted Median | IQR | ||
| Biomarkers | |||||
| hsCRP (mg/L) | 1.9 | 1.0–3.9 | 1.6 | 0.8–3.4 | 0.273 * |
| Fibrinogen (g/L) | 3.6 | 3.2–4.1 | 3.5 | 3.1–4.0 | 0.406 |
| NTproBNP (ng/L) | 99.0 | 55.0–241.0 | 100.0 | 50.0–186.0 | 0.349 * |
| Troponin (ng/L) | 3.0 | 2.0–5.0 | 3.0 | 2.0–5.0 | 0.079 * |
| Total cholesterol (mmol/L) | 4.5 | 3.9–5.2 | 4.9 | 4.1–5.4 | 0.005 |
| HDL (mmol/L) | 1.3 | 1.0–1.6 | 1.3 | 1.0–1.5 | 0.286 |
| LDL (mmol/L) | 2.3 | 1.7–3.0 | 2.7 | 2.1–3.2 | 0.005 |
| Triglycerides (mmol/L) | 1.7 | 1.2–2.4 | 1.6 | 1.2–2.3 | 0.236 |
| Peak FMD (%) † | 3.8 | 2.0–5.3 | 3.6 | 2.0–5.5 | 0.999 |
| Blood pressure | |||||
| Systolic BP (mmHg) | 132 | 120–145 | 134 | 126–146 | 0.059 |
| Diastolic BP (mmHg) | 71 | 64–79 | 74 | 67–81 | 0.059 |
| n | Weighted % | N | Weighted % | p-value | |
| ECG | |||||
| Rhythm abnormality | |||||
| No | 229 | 92.3 | 102 | 89.4 | 0.583 |
| Atrial Fibrillation | 17 | 5.6 | 12 | 8.6 | |
| Other | 7 | 2.1 | 2 | 2.1 | |
| Evidence of underlying IHD | |||||
| Yes | 57 | 15.9 | 21 | 10.9 | 0.120 |
* = Estimated using nonparametric Somers’ D statistics with sample weighting and clustering included. † = Includes 379 valid FMD tests for 220 Morwell and 159 Sale participants. Eight low quality test results were excluded. Abbreviations: IQR = inter-quartile range; hsCRP = high sensitivity C-reactive protein; NTproBNP = N-terminal pro B-type natriuretic peptide; HDL = high density lipoprotein; LDL = low density lipoprotein; FMD = flow mediated dilatation; BP = blood pressure; ECG= electrocardiograph; IHD = ischaemic heart disease.